COVID-19

Dear Partners,

Necessitated by the unprecedented situation created by Covid-19, several industry events and tradeshows across the world have been postponed or stand cancelled. While we were looking forward to meet you, we at Piramal Pharma Solutions have had to take several precautionary measures to protect both our employees and customers, worldwide.

As we move forward in these extraordinary times, we want to assure you that that we are operational by taking the right safety measures and abundant precautions to ensure that we continue to support you and your patients.

While all of us are working remotely for now, you can schedule a discussion with us and we would be glad to help ensure you meet your pharmaceutical development and supply needs and thereby, your clinical and commercial timelines.

Please feel free to reach out to us at:
Stuart.Needleman@piramal.com

Our best wishes to colleagues, friends and family.

Best Regards,
Piramal Pharma Solutions

PiramalPharma Solutions Logo

Proof of Concept Studies

With individualized programs in the offering, we offer a fast-track early-stage development service for your ADC and bioconjugate program to meet your needs.

Tailored to meet your needs

Cost-effective proof-of-concept conjugation service to demonstrate the viability of cytotoxic drugs or monoclonal antibodies for use as therapeutic ADCs.

Customer antibodies for conjugation suitability

  • Comparison of different chemistries (cysteine and lysine)
  • Range of different linkers available (cleavable, non-cleavable, and PEGylated)
  • Variety of payloads available (microtubule disrupting drugs, DNA damaging compounds, protein ribosome-inactivating toxins, and chelators for radioimmunotherapy)
  • Preparation of different drug loadings
  • Analytical characterization and screening of conjugates

Customer cytotoxic or linker technologies

  • Ability to make various conjugates with model antibodies using linker or drug platforms
  • Experienced with a range of novel linker technologies

ADC Standards to Benchmark Client Materials

  • A model antibody with DAR 2 and DAR 4 with different ADC toxins